JPWO2020230869A1 - - Google Patents

Info

Publication number
JPWO2020230869A1
JPWO2020230869A1 JP2021519492A JP2021519492A JPWO2020230869A1 JP WO2020230869 A1 JPWO2020230869 A1 JP WO2020230869A1 JP 2021519492 A JP2021519492 A JP 2021519492A JP 2021519492 A JP2021519492 A JP 2021519492A JP WO2020230869 A1 JPWO2020230869 A1 JP WO2020230869A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021519492A
Other languages
Japanese (ja)
Other versions
JPWO2020230869A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020230869A1 publication Critical patent/JPWO2020230869A1/ja
Publication of JPWO2020230869A5 publication Critical patent/JPWO2020230869A5/ja
Priority to JP2025076960A priority Critical patent/JP2025108784A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
JP2021519492A 2019-05-14 2020-05-14 Pending JPWO2020230869A1 (https=)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076960A JP2025108784A (ja) 2019-05-14 2025-05-02 Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019091700 2019-05-14
PCT/JP2020/019347 WO2020230869A1 (ja) 2019-05-14 2020-05-14 Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076960A Division JP2025108784A (ja) 2019-05-14 2025-05-02 Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物

Publications (2)

Publication Number Publication Date
JPWO2020230869A1 true JPWO2020230869A1 (https=) 2020-11-19
JPWO2020230869A5 JPWO2020230869A5 (https=) 2023-04-28

Family

ID=73289423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519492A Pending JPWO2020230869A1 (https=) 2019-05-14 2020-05-14
JP2025076960A Pending JP2025108784A (ja) 2019-05-14 2025-05-02 Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076960A Pending JP2025108784A (ja) 2019-05-14 2025-05-02 Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物

Country Status (6)

Country Link
US (1) US20220202905A1 (https=)
EP (1) EP3970796B1 (https=)
JP (2) JPWO2020230869A1 (https=)
CN (1) CN114173874B (https=)
ES (1) ES3045907T3 (https=)
WO (1) WO2020230869A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物
WO2024102746A1 (en) * 2022-11-08 2024-05-16 Microcures, Inc. Methods and agents for treating neurotrophic keratitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102375A1 (ja) * 2004-04-23 2005-11-03 Senju Pharmaceutical Co., Ltd. Ｐａｃａｐおよびその誘導体を含有する角膜神経突起形成促進剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198542A (en) * 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
JPH10505863A (ja) * 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
US20020155533A1 (en) * 1998-11-30 2002-10-24 Takeda Chemical PACAP receptor protein, method for preparing said protein, and use thereof
JP2001151799A (ja) * 1999-11-22 2001-06-05 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
WO2003051387A1 (fr) * 2001-12-19 2003-06-26 Itoham Foods Inc. Agents therapeutiques et/ou prophylactiques contre des maladies conformationnelles
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
JP2009269818A (ja) 2006-08-22 2009-11-19 Univ Showa Ｐａｃａｐペプチドを含む眼科用剤
WO2010036936A2 (en) * 2008-09-25 2010-04-01 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
US8916517B2 (en) * 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
CN101745098A (zh) * 2010-01-26 2010-06-23 暨南大学 神经多肽pacap38在制备眼部疾病的治疗、损伤修复或再生药物中的应用
WO2012127475A1 (en) 2011-03-24 2012-09-27 Neurim Pharmaceuticals (1991) Ltd. Neuroprotective peptides
JP5775356B2 (ja) 2011-05-09 2015-09-09 松本　明 神経保護作用を有するペプチド及びこれを含む薬剤
CU24075B1 (es) * 2011-08-26 2015-01-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
CN103145851B (zh) * 2013-02-22 2014-07-02 暨南大学 重组蛋白PACAP38-NtA及其编码基因与应用
WO2017027848A1 (en) 2015-08-12 2017-02-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
AT520342A1 (de) * 2017-09-07 2019-03-15 Ventrex Automotive Gmbh Ventil zum Einsatz im Tieftemperaturbereich sowie Verwendung dieses Ventils

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102375A1 (ja) * 2004-04-23 2005-11-03 Senju Pharmaceutical Co., Ltd. Ｐａｃａｐおよびその誘導体を含有する角膜神経突起形成促進剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASTROPASQUA, L. ET AL.: "Understanding the pathogenesis of neurotrophic keratitis: The role of corneal nerves.", J CELL PHYSIOL., vol. 232, JPN6020026168, 2017, pages 717 - 724, XP055760443, ISSN: 0005696554, DOI: 10.1002/jcp.25623 *
MCILVAIN, H. B. ET AL.: "Pituitary adenylate cyclase-activating peptide (PACAP) induces differentiation in the neuronal F11 c", BRAIN RES., vol. 1077, JPN6020026169, 2006, pages 16 - 23, XP027917435, ISSN: 0005696555, DOI: 10.1016/j.brainres.2005.12.130 *
ONOUE, S. ET AL.: "The neuromodulatory effects of VIP/PACAP on PC-12 cells are associated with their N-terminal structu", PEPTIDES, vol. 22, JPN6020026171, 2001, pages 867 - 872, XP055760449, ISSN: 0005696556, DOI: 10.1016/S0196-9781(01)00411-9 *

Also Published As

Publication number Publication date
WO2020230869A1 (ja) 2020-11-19
EP3970796A4 (en) 2022-12-21
CN114173874A (zh) 2022-03-11
EP3970796A1 (en) 2022-03-23
CN114173874B (zh) 2025-07-25
US20220202905A1 (en) 2022-06-30
JP2025108784A (ja) 2025-07-23
ES3045907T3 (en) 2025-12-01
EP3970796B1 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021008711A2 (https=)
BR112021017728A2 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112021017732A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021013128A2 (https=)
BR112021018484A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502